- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07941765
Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults (SAGE UTI)
SAGE-UTI: Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults: a Single-blind Randomized Controlled Trial Evaluating Outcomes in UTI
The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.
The main question this trial aims to answer is:
Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?
Participants will:
- Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
- Provide a urine sample during their initial clinic visit.
- Complete questionnaires at the initial visit and approximately 14 and 28 days later.
Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.
Panoramica dello studio
Stato
Descrizione dettagliata
**Background and Rationale**
Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.
Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.
**Trial Design**
SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.
Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:
- **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
- **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.
All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.
**Trial Procedures**
Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.
Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.
Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.
**Clinical Significance**
The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Darshika Mistry
- Numero di telefono: 6482844874
- Email: dmistry@pathnostics.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice
Descrizione
nclusion Criteria:
- Able to provide written informed consent
- Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
- A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
- Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
- Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
- Management requires microbial identification and antibiotic sensitivities from urine
- Able to provide a urine specimen (midstream voided or catheter collected)
Exclusion Criteria:
- Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
- Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
- Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate biopsy or surgery in previous 30 days)
- Currently receiving radiation therapy in the pelvic region
- Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
- Subjects with history of bladder malignancy in the past 3 years
- Subjects that have been treated with chemotherapy in the past 3 years
- Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
- Incarceration
- Pregnancy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: OTHER
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Arm A - Guidance UTI
Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing. |
|
Arm B - Standard Urine Culture:
Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent difference between diagnostic test arm in the number of composite negative outcomes
Lasso di tempo: 28 days
|
Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis) |
28 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed
Lasso di tempo: 28 days
|
Percent difference between diagnostic test arm in:
|
28 days
|
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject
Lasso di tempo: 28 days
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject |
28 days
|
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)
Lasso di tempo: 28 days
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s) |
28 days
|
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions
Lasso di tempo: 28 days
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions |
28 days
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026-SAGE-UTI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .